OGILVY RENAULT

No.: 16334

Client No.: 14140-4US

Re No.:



Facsimile

Confidentiality Message

This communication sent by facsimile is confidential, may be privileged and is intended for the exclusive use of the addressee. Any other person is strictly prohibited from disclosing, distributing or reproducing it. If the addressee cannot be reached or is unknown to you, please destroy this message and all copies. Thank you.

Number of pages including this cover sheet:

5

Date:

August 28, 2003

From:

Marc Gagné

Telephone:

(418) 640-5245

E-Mail:

mgagne@ogilvyrenault.com

To	Company - City	Phone	Fax
Ms. Georgia L. Helmer	USPTO		1-703-746-7438

Message

500 Grande Allée East Suite 520 Québec, Quobec Canada G1R 2J7

Telephone (412) 640-5000 Fax (418) 640-1500

Meighen Demers Ogilvy Renault Swabey Ogilvy Renault

Continuing the practices of



Direct Dial: (418) 640-5245/640-5988 mgagne@ogilvyrenault.com/pmarcoux@ogilvyrenault.com

SENT BY FACSIMILE

Québec, August 28, 2003

Ms. Georgia L. Helmer Art Unit 1638 USPTO Commissioner of Patents B.O. 1450 Alexandria, Virginia 2231301450

Dear Ms. Helmer:

RE: US Patent Application No. 09/678,303 – October 3, 2000

PROMOTER FOR REGULATING EXPRESSION OF FOREIGN GENES

Inventors: Louis-Philippe Vézina et al.

Our Ref.: 14149-4US

This follows our telephone conversation of yesterday (August 27, 2003) regarding the above-mentioned patent application in the USPTO. As proposed, I send you a <u>draft</u>, identified as such, of an amendment of page 5 of the disclosure and of the claims of US patent application number 09/678,303 in order to eliminate the enablement aspect due to the citation of the plasmid pGPLAS3.2 on the third line of the fist paragraph of page 5. This citation has been replaced by identification of SEQ ID NO:1 and "deletion fragment" was replaced by SEQ ID NO:2 and SEQ ID NO:3. It is believed that this would clarify this part of the protocol to allow someone skilled in the art to perform the claimed invention. The matter would now be restricted to SEQ ID NO:1, 2 and 3.

The claims have been accordingly amended. The Applicant wishes to limit the expression of DNA of interest in <u>leaves</u> of transgenic plants, and a claim 2 is deleted from the application and the claim 5 is limited to plants from the group of <u>alfalfa</u>.

The review of this <u>draft</u> amendment I respectfully propose to have a telephone discussion at your time and convenience.



Page 2

Sincerely yours,

Marc Gagné, Ph. D. Patent Agent Trainee Tel: (418) 650-5245

Fax (418) 640-1500

PMMG/np Enclosure Paul Marcoux Patent Agent -5-

HindIII and EcoRI sites of the pUC19 polycloning site. The resulting plasmid was named pBI201 and was used for further constructs. Various SEQ ID NO:2 and SEQ ID NO:3, two and deletion fragments of pGPlas3-2 SEQ ID NO:1 were operably transcriptionally and transitionally fused at the 5'terminus of the GUS reporter gene in pBI201 by RCR ligation, and these resulting constructs were used for transitory expression studies using DNA bombardment. Upon identification of the adequate deletion fragment, it was or subcloned into a binary plant expression vector such as pBI101 (Clonetech). These recombinant plasmids were used for stable integration through A. tumefaciens infection as described below.

Agrobacterium-mediated DNA transfer and regeneration of transgenic lines

The recombinant plasmids were introduced into *Agrobacterium tumefaciens* strain LBA4404 by electroporation as described in Khoudi et al (1999, *Biotechnol. Bioeng.*, <u>64</u>:135-143). Selected *Agrobacterium* strains were then co-cultivated with leaf disks from genotype C5-1 for 4 days in the absence of selection pressure (kanamycin). Following this incubation period, leaf disks were washed and pampered, and then allowed to form calli onto medium B5H. Calli were then transferred for 21 days on SH medium for embryo induction and for 28 days on BOi2Y for embryo development. Torpedo-shaped embryos were removed from Boi2Y and placed on MS medium for regeneration. Kanamycin was present in all cultivation medium except for co-cultivation and regeneration on MS. This method is described in length in Desgagnés et al (1995, *Plant Cell Tissue Organ Cult.* <u>42</u>:129-140). Rooted plantlets were grown to maturity in the greenhouse.

While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth, and as follows in the scope of the appended claims.

This page is a <u>non-official</u> document. This is a <u>Draft</u> amendment of the disclosure, and is not for official entry.

it can they had to the